MERCK KGAA O.N./ DE0006599905 /
2024-04-25 7:32:21 PM | Chg. -3.05 | Volume | Bid7:57:28 PM | Ask7:57:28 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
149.05EUR | -2.01% | 0 Turnover: 0.00 |
149.80Bid Size: 140 | 151.20Ask Size: 140 | 19.34 bill.EUR | 1.47% | 23.06 |
GlobeNewswire
1:00 PM
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA